Skip to main content
Journal cover image

Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).

Publication ,  Journal Article
Ashby, DT; Aymong, EA; Tcheng, JE; Grines, CL; Cox, DA; Mehran, R; Garcia, E; Griffin, JJ; Guagliumi, G; Stuckey, T; Turco, M; Lansky, AJ ...
Published in: Am J Cardiol
November 1, 2003

The utility of glycoprotein IIb/IIIa receptor inhibitors as a "bail-out" modality after unsuccessful primary percutaneous coronary intervention for acute myocardial infarction is unknown. In the CADILLAC trial, of 1,030 control patients, 62 patients (6.0%) crossed over and received abciximab for procedural complications or suboptimal angioplasty results. Compared with patients who received routine upfront abciximab, those treated with bail-out abciximab had markedly lower rates of Thrombolysis In Myocardial Infarction grade 3 flow and increased rates of hemorrhagic and ischemic complications at 30 days and 1 year.

Duke Scholars

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

November 1, 2003

Volume

92

Issue

9

Start / End Page

1091 / 1094

Location

United States

Related Subject Headings

  • Treatment Failure
  • Prospective Studies
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Intraoperative Complications
  • Immunoglobulin Fab Fragments
  • Humans
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ashby, D. T., Aymong, E. A., Tcheng, J. E., Grines, C. L., Cox, D. A., Mehran, R., … CADILLAC Trial. (2003). Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). Am J Cardiol, 92(9), 1091–1094. https://doi.org/10.1016/j.amjcard.2003.06.005
Ashby, Dale T., Eve A. Aymong, James E. Tcheng, Cindy L. Grines, David A. Cox, Roxana Mehran, Eulogio Garcia, et al. “Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).Am J Cardiol 92, no. 9 (November 1, 2003): 1091–94. https://doi.org/10.1016/j.amjcard.2003.06.005.
Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, et al. Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). Am J Cardiol. 2003 Nov 1;92(9):1091–4.
Ashby, Dale T., et al. “Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).Am J Cardiol, vol. 92, no. 9, Nov. 2003, pp. 1091–94. Pubmed, doi:10.1016/j.amjcard.2003.06.005.
Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Lansky AJ, Stone GW, CADILLAC Trial. Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). Am J Cardiol. 2003 Nov 1;92(9):1091–1094.
Journal cover image

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

November 1, 2003

Volume

92

Issue

9

Start / End Page

1091 / 1094

Location

United States

Related Subject Headings

  • Treatment Failure
  • Prospective Studies
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Intraoperative Complications
  • Immunoglobulin Fab Fragments
  • Humans
  • Follow-Up Studies